» Articles » PMID: 17785366

Progesterone Receptor Regulates Bcl-2 Gene Expression Through Direct Binding to Its Promoter Region in Uterine Leiomyoma Cells

Overview
Specialty Endocrinology
Date 2007 Sep 6
PMID 17785366
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Uterine leiomyomas are smooth muscle cell tumors that cause irregular uterine bleeding and pregnancy loss in many reproductive-age women. Progesterone stimulates their growth, whereas treatment with progesterone receptor (PR) antagonists or selective progesterone receptor modulators shrinks these tumors. Molecular mechanisms underlying these observations are unknown.

Objective: Bcl-2 is a key protein that inhibits apoptosis. It was proposed that growth enhancement of leiomyoma cells by progesterone was mediated via bcl-2 induction. Here we test the hypothesis that PR regulates the bcl-2 gene by directly binding to its promoter.

Results: The pure progesterone agonist R5020 increased the total number of viable primary human leiomyoma smooth muscle (LSM) cells in culture. Progesterone or R5020 (10(-6) m) significantly increased bcl-2 mRNA levels after 2 and 4 h by 9.2- and 3.4-fold, respectively, in LSM cells. Transient transfection with deletion mutants of bcl-2 promoter showed that the -1281/-258-bp region conferred responsiveness to progesterone induction in the presence of PR-A. We identified a palindromic progesterone response element (PRE) at -553/-539 bp. EMSA showed that PR in nuclear extracts from LSM cells bound specifically to this PRE. Chromatin immunoprecipitation-PCR confirmed in situ recruitment of PR to the -629/-388-bp region bearing the PRE. In vivo, bcl-2 mRNA levels correlated significantly with total PR mRNA levels in leiomyoma tissues.

Conclusion: Taken together, progesterone via PR interacts with the bcl-2 promoter to induce its expression in leiomyoma tissue. This may explain, in part, the progesterone-dependent enhancement of growth in uterine leiomyoma.

Citing Articles

Establishment of a 3D spheroid culture system to evaluate the responsiveness of uterine leiomyoma cells to female hormones.

Sakai T, Sato S, Tamehisa T, Takasaki H, Kajimura T, Tamura I Reprod Med Biol. 2025; 24(1):e12627.

PMID: 39845479 PMC: 11751880. DOI: 10.1002/rmb2.12627.


Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities.

Ploumaki I, Macri V, Segars J, Islam M Life Sci. 2024; 362():123345.

PMID: 39740758 PMC: 11755406. DOI: 10.1016/j.lfs.2024.123345.


Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics.

Ali M, Ciebiera M, Vafaei S, Alkhrait S, Chen H, Chiang Y Cells. 2023; 12(8).

PMID: 37190026 PMC: 10136461. DOI: 10.3390/cells12081117.


Comparative- and network-based proteomic analysis of bacterial chondronecrosis with osteomyelitis lesions in broiler's proximal tibiae identifies new molecular signatures of lameness.

Cook J, Greene E, Ramser A, Mullenix G, Dridi J, Liyanage R Sci Rep. 2023; 13(1):5947.

PMID: 37045932 PMC: 10097873. DOI: 10.1038/s41598-023-33060-y.


Clinical Utility of Mifepristone: Apprising the Expanding Horizons.

Karena Z, Shah H, Vaghela H, Chauhan K, Desai P, Chitalwala A Cureus. 2022; 14(8):e28318.

PMID: 36158399 PMC: 9499832. DOI: 10.7759/cureus.28318.